Informuta Secured $1.25 Million NSF Grant

The New Orleans-based startup received federal funding to advance its AI-powered antibiotic resistance prediction platform.

Updated on Sept. 23, 2026 in Life Sciences

Bold vector editorial illustration of glass petri dishes and sequencing slides on a clinical surface, representing medical technology and research. — New Orleans-based startup Informuta secured a $1.25 million NSF grant to accelerate the clinical implementation of its AI-driven antibiotic resistance prediction platform. AI Illustration. Upload story photo >

Live Poll

Do you trust artificial intelligence to accurately predict how your infections respond to antibiotic treatments?

Informuta has been awarded a $1.25 million Small Business Innovation Research Phase II grant from the National Science Foundation. The funding supports the clinical implementation of its AI-driven predictive technology for identifying antibiotic resistance in hospital environments.

Why it matters

The grant enables the company to transition from scientific development to clinical infrastructure and the generation of prospective clinical evidence. This shift is essential for integrating advanced genomic tools into routine antimicrobial stewardship and hospital workflows.

The project utilizes whole-genome sequencing combined with predictive genomic biomarkers and artificial intelligence to identify resistant bacteria. Informuta is currently working to secure Clinical Laboratory Improvement Amendments certification and College of American Pathologists accreditation.

The players

Informuta

A biotechnology company that uses artificial intelligence to predict antibiotic resistance in bacteria.

National Science Foundation

A United States government agency that supports fundamental research and education in all the non-medical fields of science and engineering.

Tulane University

A private research university in New Orleans that served as the original birthplace of the Informuta spin-out.

Ryan Shields

A member of the expanded Informuta leadership team.

The details

Operating from the New Orleans BioInnovation Center, Informuta is testing its platform using clinical isolates in partnership with the University of Pittsburgh Medical Center and the University of California, Irvine. The company also expanded its leadership team by appointing a new chief medical officer, a vice president of clinical microbiology, and a lab director.

Informuta was founded and spun out of Tulane University in 2023.
The startup won the New Orleans BioInnovation Center's BioChallenge pitch competition in 2024.
The receipt of the Phase II grant was announced in September 2026.

The Big Picture

This award follows the standard federal funding pattern intended to bridge the gap between basic scientific research and market-ready clinical technology. The project represents a broader transition within the life sciences toward deploying AI-driven genomic analysis for real-time patient diagnostics.

The successful integration of this predictive technology could lead to faster and more accurate antibiotic prescriptions for patients in hospital settings. This helps reduce the misuse of antibiotics and limits the spread of resistant bacterial infections.

The takeaway

This funding underscores the growing importance of utilizing artificial intelligence to solve critical problems in public health. Researchers and hospital systems should continue to monitor how these genomic predictive models improve patient outcomes compared to traditional diagnostic methods.